JP2024520188A5 - - Google Patents

Info

Publication number
JP2024520188A5
JP2024520188A5 JP2023561035A JP2023561035A JP2024520188A5 JP 2024520188 A5 JP2024520188 A5 JP 2024520188A5 JP 2023561035 A JP2023561035 A JP 2023561035A JP 2023561035 A JP2023561035 A JP 2023561035A JP 2024520188 A5 JP2024520188 A5 JP 2024520188A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023561035A
Other languages
English (en)
Japanese (ja)
Other versions
JP7579990B2 (ja
JP2024520188A (ja
Filing date
Publication date
Priority claimed from EP21170941.5A external-priority patent/EP4066899A1/en
Priority claimed from EP21172723.5A external-priority patent/EP4086284A1/en
Application filed filed Critical
Priority claimed from PCT/EP2022/058626 external-priority patent/WO2022207822A1/en
Publication of JP2024520188A publication Critical patent/JP2024520188A/ja
Publication of JP2024520188A5 publication Critical patent/JP2024520188A5/ja
Application granted granted Critical
Publication of JP7579990B2 publication Critical patent/JP7579990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023561035A 2021-03-31 2022-03-31 抗ネクチン－４抗体およびその使用 Active JP7579990B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21166441.2 2021-03-31
EP21166441 2021-03-31
EP21170941.5 2021-04-28
EP21170941.5A EP4066899A1 (en) 2021-03-31 2021-04-28 Anti-nectin-4 antibody
EP21172723.5 2021-05-07
EP21172723.5A EP4086284A1 (en) 2021-05-07 2021-05-07 Anti-nectin-4 antibody exatecan conjugates
EP21209332.2 2021-11-19
EP21209332 2021-11-19
PCT/EP2022/058626 WO2022207822A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4-antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2024520188A JP2024520188A (ja) 2024-05-22
JP2024520188A5 true JP2024520188A5 (enExample) 2024-08-13
JP7579990B2 JP7579990B2 (ja) 2024-11-08

Family

ID=80999114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023561116A Active JP7579991B2 (ja) 2021-03-31 2022-03-31 抗ネクチン－４抗体エキサテカンコンジュゲート
JP2023561035A Active JP7579990B2 (ja) 2021-03-31 2022-03-31 抗ネクチン－４抗体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023561116A Active JP7579991B2 (ja) 2021-03-31 2022-03-31 抗ネクチン－４抗体エキサテカンコンジュゲート

Country Status (18)

Country Link
US (4) US20240173424A1 (enExample)
EP (2) EP4314057A1 (enExample)
JP (2) JP7579991B2 (enExample)
KR (2) KR20240028330A (enExample)
AU (2) AU2022250867A1 (enExample)
BR (1) BR112023017728A2 (enExample)
CA (2) CA3212655A1 (enExample)
CL (2) CL2023002907A1 (enExample)
CO (2) CO2023012821A2 (enExample)
CR (2) CR20230469A (enExample)
DO (2) DOP2023000213A (enExample)
EC (2) ECSP23073625A (enExample)
IL (2) IL305954A (enExample)
JO (2) JOP20230238A1 (enExample)
MX (2) MX2023011563A (enExample)
PE (2) PE20240724A1 (enExample)
SA (1) SA523450918B1 (enExample)
WO (3) WO2022207822A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023011563A (es) * 2021-03-31 2024-02-08 Emergence Therapeutics Gmbh Conjugados de anticuerpo anti-nectina-4 y exatecano.
EP4285935A1 (en) * 2022-06-03 2023-12-06 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4344707A1 (en) * 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates
EP4461317A1 (en) * 2023-05-12 2024-11-13 Emergence Therapeutics GmbH Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
EP4725964A1 (en) * 2023-06-08 2026-04-15 Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. Antibody binding to nectin-4 and use thereof
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130088116A (ko) * 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
EP3347048B1 (en) * 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
EP3546448B1 (en) * 2016-11-25 2022-04-06 Mabwell (Shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
US11274160B2 (en) * 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
EP3700577A1 (en) * 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
WO2020216947A1 (en) * 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
AU2020364959B2 (en) * 2019-10-07 2026-07-09 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for Nectin-4 and uses thereof
WO2021143741A1 (zh) * 2020-01-15 2021-07-22 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
CN114845740B (zh) * 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
MX2023011563A (es) * 2021-03-31 2024-02-08 Emergence Therapeutics Gmbh Conjugados de anticuerpo anti-nectina-4 y exatecano.
EP4534101A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Similar Documents

Publication Publication Date Title
JP2024515536A5 (enExample)
US10407506B2 (en) Anti-MCAM antibodies and associated methods of use
JP2022506072A5 (enExample)
JP2019527553A5 (enExample)
JP2020513791A5 (enExample)
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
RU2009107494A (ru) АНТИТЕЛА К ErbB2
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP7726534B2 (ja) 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
EP3725806A1 (en) Bispecific antibody to a-syn/igf1r and use thereof
JP2018522888A5 (enExample)
JP2021520832A5 (enExample)
JP2024001073A5 (enExample)
JP2020521504A (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
IL305951A (en) Anti-nectin-4 antibodies and their uses
JP2021511387A5 (enExample)
RU2011151287A (ru) АНТИ Notch-1 АНТИТЕЛА
WO2014065402A1 (ja) 抗ヒトｃｄ４０モノクローナル抗体及びその利用
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
JP2023522212A5 (enExample)
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2023509214A5 (enExample)
JP2022521305A (ja) 抗ｐｄ－ｌ１抗体及びその使用